PD0325901

Licensed by Pfizer Catalog No.S1036

PD0325901 Chemical Structure

Molecular Weight(MW): 482.19

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

18 Customer Reviews

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    Immunoblot analysis of Ser9-phosphorylated (that is, inactivated) or total GSK3β, active or total β-catenin Thr202- and Tyr204- phosphorylated or total Erk1/2, and Ser473-phosphorylated or total Akt in control; Bcl2 lymphoma cells treated with ADR for five days, together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways.α -Tubulin was used as a loading control. MAPKi=PD325901.

    Nature, 2018, 553(7686):96-100. PD0325901 purchased from Selleck.

  • c, Examples of CDK2 activity traces aligned to the end of mitosis. Each panel shows different time windows relative to mitosis when mitogens were withdrawn (marked in grey) in d. d, Probability of proliferation (defined as CDK2 activity > 1, 10 h after mitosis) represented as a function of time when inhibitors of MEK (MEKi; 100 nM PD0325901) or of CDK4 (CDK4i; 1 μ M palbociclib) were added or when mitogens were removed, relative to mitosis. Data are mean ± s.e.m. (n = 5 biological replicates).

    Nature, 2017. PD0325901 purchased from Selleck.

    Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

  • Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

    Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

  • (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

    Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

  • Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

     

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

  •  

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

    The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

  • PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

    Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Targets
MEK [1]
(Cell-free assay)
0.33 nM
In vitro

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. [1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. [2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. [2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. [3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell NHvSfFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\zTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42Ojdibl2u NEjFTWhUSU6JRWK=
human M14 cell NUn5TG8yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYrzTpE{UW6qaXLpeIlwdiCxZjDoeY1idiCPMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ2KG6PLh?= MojmV2FPT0WU
human SK-MEL-28 cell NV;1UZpGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTJibl2u MXLTRW5ITVJ?
human NOMO-1 cell M1Twb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLJTY5pcWKrdHnvckBw\iCqdX3hckBPV02RLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA4KG6PLh?= MYLTRW5ITVJ?
human A375 cell MoHQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnfBTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62PUBvVS5? MlmyV2FPT0WU
human DU-4475 cell M3WzRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3hUXJKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=> MnjGV2FPT0WU
human C32 cell NHu1fHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGM{OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkegcm0v M1LkS3NCVkeHUh?=
human BPH-1 cell MnzRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;hXmZKdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46PSCwTT6= NHrOdnVUSU6JRWK=
human CP50-MEL-B cell NFzUWIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2W0RmlvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNUigcm0v NY[0eo1[W0GQR1XS
human H9 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVfwXVZKUW6qaXLpeIlwdiCxZjDoeY1idiCKOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|chdk1w NEjxW|JUSU6JRWK=
human HTC-C3 cell NGjHT4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhVSy2FMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPFkhdk1w NVfifYJXW0GQR1XS
human BHT-101 cell NWnZNJVMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{Dvd2lvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPyCwTT6= MXPTRW5ITVJ?
human COLO-741 cell Mn[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\TOmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23OFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjFibl2u M3jqXnNCVkeHUh?=
human OVCAR-5 cell Mnv0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{WwVWlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvQDJibl2u M1XQN3NCVkeHUh?=
human A549 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7GTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVS5? NX7BWFRZW0GQR1XS
human SH-4 cell growth M4nTN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPicFJKdmirYnn0bY9vKG:oIHj1cYFvKFOKLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3KG6PLh?= NE\O[mNUSU6JRWK=
human SK-N-AS cell NGPEW5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fU[WlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3BV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPDRibl2u MWLTRW5ITVJ?
human HT-144 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuPVchdk1w NWfRdoo1W0GQR1XS
human MEL-HO cell NFzudpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TiNmlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTT6= MV\TRW5ITVJ?
human COLO-679 cell MknVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEL5NpFKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMEGgcm0> M2\ZZ3NCVkeHUh?=
human HuP-T4 cell MmG3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3vicmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvQThibl2u NHHlcppUSU6JRWK=
human H-EMC-SS cell NILT[ZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvODJibl2u MoDjV2FPT0WU
human LB2518-MEL cell NGTkUmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjVzOD3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5zMzDuUU4> NXKzWlBxW0GQR1XS
human HL-60 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHDb417UW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjF3IH7NMi=> NYj1SnF[W0GQR1XS
human NCI-H1666 cell NEPJbWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4DkT2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwMUegcm0v NHTwSoJUSU6JRWK=
human A101D cell NGHaZ|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGEyODGGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuOFUhdk1w MW\TRW5ITVJ?
human RVH-421 cell NFGybG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7YTY5pcWKrdHnvckBw\iCqdX3hckBTXkhvNEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIvPjRibl2u MoHkV2FPT0WU
human Hs-578-T cell NYrz[WVrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rLcWlvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOi55OTDuUU4> M1znW3NCVkeHUh?=
human A375 cells MXvQdo9tcW[ncnH0bY9vKGG|c3H5 NFXLelU4OiCq Mme2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHX4dJJme3OrbnegRnJCTiCYNkCwSUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIwhfGm2ZYKt[4xwKGG|c3H5MEBKSzVyPUGzJI5ONg>? M3vtdVI{PDd2M{i4
human DOK cell NUXm[JVJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo\zTY5pcWKrdHnvckBw\iCqdX3hckBFV0tiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz60JI5ONg>? MYfTRW5ITVJ?
human Mewo cell NETY[GpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHv1dItKdmirYnn0bY9vKG:oIHj1cYFvKE2nd3:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE41PSCwTT6= MUTTRW5ITVJ?
human ONS-76 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGO5cotKdmirYnn0bY9vKG:oIHj1cYFvKE:QUz23OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjVzIH7NMi=> MVjTRW5ITVJ?
human UACC-257 cell M1r0Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnH3TY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZ{IH7NMi=> NYGxTFd{W0GQR1XS
human SW626 cell M2f0NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHr5T5hKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvQTFibl2u NXvzcGVMW0GQR1XS
human SW620 cell NUj0R|FDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DSd2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46PSCwTT6= NHvCd2pUSU6JRWK=
human TYK-nu cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHXRRoFKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjF|IH7NMi=> M1fHPXNCVkeHUh?=
human ACN cell NH\hT4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PEXmlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuO|Yhdk1w Mn;DV2FPT0WU
human MIAPaCa2 cells NHH2R3RRem:uaX\ldoF1cW:wIHHzd4F6 M{fQZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMtKEmFNUC9NVchdk1w NWfpfWlbOjN2N{SzPFg>
human T-24 cell NF;2SJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIntUFJKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU44OSCwTT6= MlLjV2FPT0WU
human AGS cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkSxJI5ONg>? NVPvU|hDW0GQR1XS
human SW872 cell MoTnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HLWGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{46QSCwTT6= NXLkVWtNW0GQR1XS
human C2BBe1 cell NUPueoFlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFrGZ|RKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjV2IH7NMi=> MYfTRW5ITVJ?
human MZ7-mel cell MlnzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\y[lBzUW6qaXLpeIlwdiCxZjDoeY1idiCPWketcYVtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjlwNEOgcm0v NHnlWI5USU6JRWK=
human HCC2998 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{43PiCwTT6= M2G3ZXNCVkeHUh?=
human HO-1-N-1 cell NVvvN5NQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnwNVlKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEOgcm0v MoL0V2FPT0WU
human SW756 cell MkfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7rVVhqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR3IH7NMi=> Mne3V2FPT0WU
human NCI-H1437 cell NYLMempIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{WxWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOFM4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEmgcm0v NFj6RpRUSU6JRWK=
human NCI-H747 cell MoDTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF3DTVFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwOUigcm0v MV3TRW5ITVJ?
human SK-MEL-2 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVywNVNVUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN3LkKgcm0v MoToV2FPT0WU
human MZ2-MEL cell NHvXXIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYr4PWhxUW6qaXLpeIlwdiCxZjDoeY1idiCPWkKtUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzVwNkWgcm0v NHTjRYtUSU6JRWK=
human PSN1 cell MonRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|OD60OUBvVQ>? MYLTRW5ITVJ?
human CAL-39 cell MmHTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE[yfZlKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjB2IH7NMi=> MojhV2FPT0WU
human LOXIMVI cell MnXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4{QSCwTT6= M3X3VnNCVkeHUh?=
human COLO-792 cell NVzweFRzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFMvOTVibl2u MlHrV2FPT0WU
human CAL-27 cell M3LwfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlkyKG6P MlHjV2FPT0WU
human AsPC-1 cell MkPRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEe0NJFKdmirYnn0bY9vKG:oIHj1cYFvKEG|UFOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjJ6IH7NMi=> NXLuTGZoW0GQR1XS
human NCI-H2291 cell NEjFOIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{e2TmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlkyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDZwNE[gcm0v M2LzU3NCVkeHUh?=
human RCM-1 cell NVfvWnRFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGnae41KdmirYnn0bY9vKG:oIHj1cYFvKFKFTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFYvQDVibl2u MV7TRW5ITVJ?
human NCI-H292 cell M1qwPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFcvOzlibl2u MnPZV2FPT0WU
human WM-115 cell MnvRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvvcGN{UW6qaXLpeIlwdiCxZjDoeY1idiCZTT2xNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01QC53IH7NMi=> MX3TRW5ITVJ?
human RT-112 cell Mn;mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS4Mlg1KG6PLh?= MW\TRW5ITVJ?
human HT-29 cell NGW2[4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGP4T5BKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVAvPDlibl2u MXnTRW5ITVJ?
human RKO cell growth NHPvXo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUC4WnByUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk4xOiCwTT6= MmjZV2FPT0WU
human KY821 cell NVv5So5{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGt[QDJzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOuN{BvVS5? MkL3V2FPT0WU
human LB1047-RCC cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTCZpVKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13OT62OUBvVS5? MVTTRW5ITVJ?
human SW1116 cell NHOxUlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVHUS21WUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GxNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03OC52OTDuUU4> NGTLb3VUSU6JRWK=
human P12-ICHIKAWA cell NVW3PWVrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHAyOi2LQ1jJT2FYSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ{LkK3JI5ONg>? M3ixOXNCVkeHUh?=
human HCC70 cell NHvpU4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;CNWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFN{CgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22N{4xOSCwTT6= NFzE[HlUSU6JRWK=
human MIA-PaCa-2 cell MliyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUf2VppxUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkOuOVMhdk1w NYn3dGxjW0GQR1XS
human LoVo cell NUDlXnZPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT6yPUBvVS5? MVHTRW5ITVJ?
human LB2241-RCC cell NXvBZXR1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rQXGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ3LkWyJI5ONg>? NIfwT4tUSU6JRWK=
human GAK cell M4XOO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2fyNmlvcGmkaYTpc44hd2ZiaIXtZY4hT0GNIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nk[uPFchdk1w MonUV2FPT0WU
human RD cell MnviS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVTFWWdTUW6qaXLpeIlwdiCxZjDoeY1idiCURDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[3MlEhdk1w MV3TRW5ITVJ?
human KNS-62 cell M33xfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIT3UJNKdmirYnn0bY9vKG:oIHj1cYFvKEuQUz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY6Njl7IH7NMi=> MoCzV2FPT0WU
human HD-MY-Z cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTLVFMzUW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzFwMUKgcm0v NVLhbVhXW0GQR1XS
human COR-L105 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1LtOGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04OS55MTDuUU4> MUDTRW5ITVJ?
human IA-LM cell Mn;FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGlCNUyPIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;N{OuNlghdk1w MX\TRW5ITVJ?
human EM-2 cell NXvtcmt1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15ND63JI5ONg>? NW\kPIFSW0GQR1XS
human NB69 cell Mm\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NVjKeFAzW0GQR1XS
human HuP-T3 cell NFTSUllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVr4eFc6UW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Oy57MzDuUU4> NF7TWFJUSU6JRWK=
human BB30-HNC cell NFm2dVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fhSWlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05PS53MTDuUU4> Mn\WV2FPT0WU
human HT-1080 cell MlHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXrYWlR[UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwOEigcm0v NE\VbG5USU6JRWK=
human RMG-I cell MmnkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYXnclZLUW6qaXLpeIlwdiCxZjDoeY1idiCUTVetTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjN2IH7NMi=> M2DFfnNCVkeHUh?=
human HCC1419 cell MnjwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfCRVZKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06OS5|ODDuUU4> NH3IfFhUSU6JRWK=
human SW780 cell M4XhOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlTXTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmyMlMzKG6PLh?= M{fTeHNCVkeHUh?=
human SNU-387 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2nUU2lvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk{NjN4IH7N NFHFRY1USU6JRWK=
human LAMA-84 cell MlnFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25OE43QCCwTT6= M3\VcnNCVkeHUh?=
human MV-4-11 cell M2HIbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1;mRWlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1Njd|IH7NMi=> NVzUVppFW0GQR1XS
human EGI-1 cell NFnRbINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXSTY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm1MlgyKG6PLh?= NFLocXdUSU6JRWK=
human NCI-SNU-1 cell M1vj[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk3Njd|IH7NMi=> MYjTRW5ITVJ?
human MEG-01 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvYPIpKdmirYnn0bY9vKG:oIHj1cYFvKE2HRz2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk4Njd5IH7NMi=> NF7pRnRUSU6JRWK=
human OMC-1 cell M{nVXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrMTY5pcWKrdHnvckBw\iCqdX3hckBQVUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwNE4zOyCwTT6= M{XsRXNCVkeHUh?=
human NB10 cell NG[4dHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjHNHY1UW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAxNjR{IH7NMi=> NXLQcVNNW0GQR1XS
human CAL-62 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwNE44QCCwTT6= NEC1TFlUSU6JRWK=
human NCI-H2087 cell NH;a[pNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWXhSlgzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEGuNVQhdk1w NWW2O|FxW0GQR1XS
human MDA-MB-175-VII cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmDhTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVc2NV[LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 MXrTRW5ITVJ?
human LS-513 cell NFvBc25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxUNTVzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxOE45OyCwTT6= NUTacIRXW0GQR1XS
human HN cell growth Mn:wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF3pXm9KdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKyMlU6KG6PLh?= M3XaW3NCVkeHUh?=
human ABC-1 cell NYH6RXdTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKzMlAzKG6PLh?= NWH5SIE4W0GQR1XS
human SJSA-1 cell M4rBW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M16ybGlvcGmkaYTpc44hd2ZiaIXtZY4hW0qVQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVI{NjF7IH7NMi=> NH\UcIFUSU6JRWK=
human PANC1 cells NGPEUYtHfW6ldHnvckBie3OjeR?= MYqxNEDPxE1? MUmxJIg> MXvJcohq[mm2aX;uJI9nKE2HS{GgbY4hcHWvYX6gVGFPSzFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJBGemtzL{KgcIV3\WxiYYSgNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz MkXjNlU4PjZ4M{O=
human MCF7 cells M{TIfWZ2dmO2aX;uJIF{e2G7 MnS2O|UhdWmwcx?= NHHw[HlKdmirYnn0bY9vKG:oIF3Fb|EwOiCrbjDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25iYX\0[ZIhPzVibXnud{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ NIXoU4kzOzN7OES1Ny=>

... Click to View More Cell Line Experimental Data

In vivo The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. [2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. [2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. [3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. [3]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro cascade assay:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: PTC cells
  • Concentrations: 0.1 nM- 1 μM
  • Incubation Time: 48 hours
  • Method:

    PTC cells (1 × 104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T0)/(C − T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Ncr-nu/nu mice bearing PTC cells
  • Formulation: 80 mM citric buffer (pH 7)
  • Dosages: 20-25 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG 400+5% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.19
Formula

C16H14F3IN2O4

CAS No. 391210-10-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumour|Colorectal Cancer University of Oxford|Queens University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall dHebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings November 2014 Phase 1
NCT02096471 Active, not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02022982 Recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 Phase 1
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • Answer:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD0325901 | PD0325901 supplier | purchase PD0325901 | PD0325901 cost | PD0325901 manufacturer | order PD0325901 | PD0325901 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID